CHI3L1 and pancreatic neoplasm: In our study, lower baseline CHI3L1 levels were observed in patients with CR/PR/SD (47.4 ng/ml) compared to PD patients (64.7 ng/ml), suggesting that plasmatic CHI3L1 level may be a predictive biomarker for VT1021 in patients with GBM and pancreatic cancer (Table 5).